Short answer. Yes. RA 9165 requires the Board to, within five days from the date of its promulgation, submit to Congress a detailed reclassification, addition, or removal of any drug from the list of dangerous drugs — a mandatory reporting duty that follows every such action.
What the law says
The Board shall, within five (5) days from the date of its promulgation submit to Congress a detailed reclassification, addition, or removal of any drug from the list of dangerous drugs.
RA 9165, Section 93 — Reclassifying Or Delisting A Drug. Read the full provision →
The Board's power to reclassify drugs
Section 93 gives the Board this authority directly: the Board shall have the power to reclassify, add to or remove from the list of dangerous drugs. Reclassification is not a power exercised in secret — the provision surrounds it with a defined process, from who may start it through public notice, ending in the reporting duty to Congress your question asks about.
Who can start the process
The process is not limited to the Board acting on its own: proceedings to reclassify, add, or remove a drug or other substance may be initiated by the PDEA, the DOH, or by petition from any interested party, including the manufacturer of a drug, a medical society or association, a pharmacy association, a public interest group concerned with drug abuse, a national or local government agency, or an individual citizen. Once a petition or investigation begins, the Board evaluates factors such as the drug's potential for abuse, its pharmacological effects, and its risk to public health.
Public notice before any reclassification takes effect
Before finalizing a reclassification, the Board must also inform the public: the Dangerous Drugs Board shall give notice to the general public of the public hearing of the reclassification, addition to or removal from the list of any drug by publishing such notice in any newspaper of general circulation once a week for two (2) weeks. This publication step precedes the reporting duty owed to Congress, giving the public a chance to weigh in before the change is finalized and reported.
The five-day report to Congress
Once a reclassification, addition, or removal is promulgated, Section 93 requires a specific follow-up step: the Board shall, within five (5) days from the date of its promulgation submit to Congress a detailed reclassification, addition, or removal of any drug from the list of dangerous drugs. This reporting duty is mandatory and time-bound — five days from promulgation — for every such action the Board takes, whether the change adds a drug to the list, removes one, or simply reclassifies it into a different category.